Rhumbline Advisers reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 398,763 shares of the medical research company’s stock after selling 2,784 shares during the period. Rhumbline Advisers’ holdings in Edwards Lifesciences Corporation were worth $47,150,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EW. Sabal Trust CO boosted its stake in Edwards Lifesciences Corporation by 0.5% in the second quarter. Sabal Trust CO now owns 2,934 shares of the medical research company’s stock worth $347,000 after buying an additional 14 shares in the last quarter. Alexandria Capital LLC boosted its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in Edwards Lifesciences Corporation by 3.5% in the first quarter. Quadrant Capital Group LLC now owns 1,209 shares of the medical research company’s stock worth $109,000 after buying an additional 41 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Edwards Lifesciences Corporation by 1.6% in the first quarter. Rehmann Capital Advisory Group now owns 3,393 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares in the last quarter. Finally, M Holdings Securities Inc. boosted its stake in Edwards Lifesciences Corporation by 1.5% in the first quarter. M Holdings Securities Inc. now owns 4,132 shares of the medical research company’s stock worth $389,000 after buying an additional 62 shares in the last quarter. Institutional investors and hedge funds own 84.15% of the company’s stock.

Edwards Lifesciences Corporation (NYSE:EW) opened at 114.50 on Friday. The firm has a market capitalization of $24.18 billion, a price-to-earnings ratio of 34.73 and a beta of 0.63. The stock has a 50 day moving average price of $116.95 and a 200 day moving average price of $105.35. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842 million for the quarter, compared to analyst estimates of $839.16 million. During the same period in the prior year, the firm posted $0.76 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://theolympiareport.com/2017/08/12/edwards-lifesciences-corporation-nyseew-shares-sold-by-rhumbline-advisers.html.

EW has been the subject of a number of recent research reports. Stifel Nicolaus lifted their price objective on Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the stock a “buy” rating in a research report on Wednesday, April 26th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 26th. Jefferies Group LLC reiterated a “buy” rating on shares of Edwards Lifesciences Corporation in a research report on Wednesday, April 26th. Vetr cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating and set a $110.88 price objective for the company. in a research report on Wednesday, April 26th. Finally, Goldman Sachs Group, Inc. (The) initiated coverage on Edwards Lifesciences Corporation in a research report on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 price objective for the company. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $121.13.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $118.05, for a total value of $3,883,845.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Patrick B. Verguet sold 11,500 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $111.64, for a total value of $1,283,860.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 183,412 shares of company stock worth $21,176,230. Insiders own 2.13% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.